Research
Sermorelin: what the evidence actually shows
Sermorelin genuinely moves the growth hormone axis, which is why it was once an approved diagnostic agent. But the trials that would show it changes how a healthy adult looks, sleeps, recovers or ages have not been done.
- The Sermorelin board scores the sellers that publish a Sermorelin price, on what each one discloses.
- Set against another compound on the same evidence standard: Sermorelin vs CJC-1295, Sermorelin vs growth hormone, Sermorelin vs ipamorelin and Sermorelin vs tesamorelin.
What sermorelin is
Sermorelin is a synthetic fragment of growth-hormone-releasing hormone: the first twenty-nine amino acids of the natural hormone. That is the shortest piece that still carries its activity. It is not growth hormone. It is a signal that tells the pituitary gland to release the growth hormone it already makes.
That distinction is the whole reason sermorelin exists as a product. Growth hormone injected from outside overrides the body's own control loop. Sermorelin works one step upstream, at the receptor the body uses itself. The release it triggers still passes through the pituitary, and it is still subject to the braking signals that normally limit it.
Sermorelin is not a new or obscure molecule. It was approved and sold in the United States under the brand name Geref. One use was diagnostic: assessing whether a pituitary gland could secrete growth hormone on demand. In a separate presentation, it was approved for growth failure in children with growth hormone deficiency. The manufacturer discontinued it, and it is no longer marketed here as an approved product. Everything currently sold as sermorelin in the United States is a compounded preparation.
The part that is real
Sermorelin provokes a growth hormone response. This is not a marketing claim that needs defending — it is the property the diagnostic product was approved on. A test that asks whether a pituitary gland can respond only works if the agent reliably makes a working pituitary respond, and sermorelin was accepted as that agent.
Downstream of that, growth hormone drives the liver to produce insulin-like growth factor 1. IGF-1 is the blood marker most clinics use to say a course of sermorelin is working. So when a clinic tells a patient that their numbers moved, the numbers plausibly did move. The mechanism is not in dispute.
This is why sermorelin is graded limited evidence rather than none. There is a real, measurable, well-characterized pharmacological effect here, and the sites that treat sermorelin as interchangeable with the research-vial compounds are being unfair to it.
What that does not tell you
A hormone level is not an outcome. It is a proxy for one, and it is only a good proxy once somebody has demonstrated that moving it moves the thing you actually care about.
The uses sermorelin is marketed for in the adult wellness market are outcomes: body composition, sleep quality, energy, exercise recovery, skin, and the general promise of slowing down how aging feels. None of them are IGF-1. Establishing whether sermorelin delivers them would take trials in the population being sold the product. Those trials would have to run long enough for the outcome to appear, compare against placebo, and measure the outcome itself rather than the marker. That body of work is not there.
What exists instead is the diagnostic and pediatric-deficiency evidence base, built to answer completely different questions in completely different people. Alongside it sits a large volume of clinic testimonial and before-and-after reporting with no control group in it at all. Neither of those things becomes an adult efficacy trial by being cited often.
The closest relevant evidence is about growth hormone, not sermorelin
Because there is so little trial data on sermorelin in healthy adults, the argument for it usually leans on the broader literature about raising growth hormone in older people. That literature is worth knowing about, because it does not say what the marketing implies.
Studies of growth hormone administration in older adults have generally found changes in body composition measures — lean mass up, fat mass down. They did not establish that the people involved became stronger, functioned better, or lived longer. Adverse effects reported in that work include fluid retention, joint pain, carpal-tunnel-type symptoms and worsened glucose handling. The overall reading in the endocrinology literature has been skeptical rather than enthusiastic.
Two cautions apply in both directions. Those findings are about growth hormone itself, not about sermorelin, and sermorelin's supporters are right that a self-limiting upstream signal is not pharmacologically identical to a direct injection of the hormone. But the same logic cuts the other way. If the growth hormone literature does not transfer, then neither do its benefits. The case for sermorelin cannot borrow the good half of a body of evidence while disowning the rest.
The safety argument that is a mechanism, not a finding
The standard case for sermorelin over growth hormone is that release stays under the body's own feedback control, so it cannot be pushed as far and is therefore safer.
The first half of that is a fair description of the physiology. The second half is an inference. A mechanistic reason to expect fewer problems is not the same thing as a study that looked for problems over a long period in this population and did not find them. Nobody should present it as one. Notice too that the safety claim and the efficacy claim rest on the same feature: the ceiling that makes sermorelin harder to overdo is also a ceiling on how much it can do.
This page describes what is known about the compound. It carries no dosing information and is not usage guidance.
Where the regulatory question sits
Sermorelin is not currently marketed in the United States as an FDA-approved product, so everything sold here is compounded. The rules governing which substances may be compounded are actively contested rather than settled. How that question resolves is not known, and no outcome is characterized here.
What that means for a reader is narrower than it sounds. A compounded preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality, whatever the pharmacy's own standards are. That is a statement about the review pathway, not an accusation about any particular pharmacy.
Separate sermorelin, too, from material sold in vials labeled for research use only. That material sits outside the prescription supply chain entirely and carries no assurance about what is in it. Compounded sermorelin from a licensed pharmacy and a research vial bought online are not the same category of thing, and this site does not treat them as one.
How we graded this, and what would change it
Sermorelin is graded limited evidence: a real, mechanistically well-supported effect on a hormone axis, with thin long-term outcome data for the uses it is actually sold for. That is a deliberately narrow claim. It is not an endorsement, and it is not a warning.
A stronger grade has a clear price, because the bar is not mysterious. It would take a randomized, placebo-controlled trial in adults resembling the people buying it. It would measure something a person would notice rather than something a lab reports, and run long enough for a durable effect to separate from a temporary one. Tesamorelin, a different growth-hormone-releasing hormone analogue, reached FDA approval for a defined indication in a defined population by clearing roughly that bar. The standard is achievable for this class of molecule. It has not been cleared for sermorelin in the adult wellness market.
If that work is published, the grade moves. Until it is, the honest summary is that sermorelin does something measurable and that nobody has shown what that something is worth.
Key takeaways
- Sermorelin is a synthetic fragment of growth-hormone-releasing hormone, not growth hormone itself.
- It was an approved US product under the brand name Geref and was discontinued; everything sold here now is compounded.
- Its effect on the growth hormone axis is real and reproducible — that is why the grade is limited, not none.
- The outcomes it is marketed for in adults have not been tested in controlled trials of sermorelin.
- A rising IGF-1 level is a marker moving, not a demonstrated benefit.
Frequently asked questions
Is sermorelin the same as growth hormone?
No. Growth hormone is the hormone itself, given from outside the body. Sermorelin is a synthetic piece of the upstream signal that tells the pituitary gland to release its own growth hormone. The practical difference is that sermorelin's effect still passes through the body's own control loop and its normal braking signals, whereas injected growth hormone bypasses them. That difference is real. It also means sermorelin cannot push levels as far, which limits the effect as well as the risk.
Was sermorelin ever an approved drug in the United States?
Yes. It was approved and sold here under the brand name Geref, as a diagnostic agent for testing whether a pituitary gland could secrete growth hormone. A separate presentation was approved for growth failure in children with growth hormone deficiency. The manufacturer discontinued it, and it is no longer marketed in the United States as an approved product. That is why what is sold today is compounded rather than a branded prescription drug.
Does a rising IGF-1 level mean sermorelin is working?
It means the drug is doing the thing it is designed to do at the level of the hormone axis. It does not by itself mean the person will experience any of the results sermorelin is marketed for. IGF-1 is a marker, and a marker is only useful evidence of benefit once somebody has shown that moving it moves the outcome. For the adult wellness uses sermorelin is sold for, that link has not been established in controlled trials.
Why does this site grade sermorelin as limited rather than as having no evidence?
Because there genuinely is a body of human pharmacological evidence behind it. Sermorelin has a defined receptor target, a documented and reproducible effect on growth hormone release, and a history as an approved product. That is a materially different situation from a compound whose entire case rests on cell-culture and animal work. Limited evidence in these tiers means a real effect with thin long-term outcome data, and that is exactly where sermorelin sits.
What would move sermorelin to a strong evidence grade?
Randomized placebo-controlled trials in the adult population that actually buys it, measuring outcomes a person would notice rather than blood markers, and running long enough to show the effect persists. A related growth-hormone-releasing hormone analogue, tesamorelin, reached FDA approval for a specific indication by meeting a comparable standard. So this is not an impossible bar for the molecular class. It simply has not been met for sermorelin in the market where sermorelin is sold.